Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Cited In for PubMed (Select 17109680)

1.

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.

Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.

BMC Infect Dis. 2015 Mar 26;15(1):156. doi: 10.1186/s12879-015-0888-x.

2.

Direct-acting antiviral agents in patients with hepatitis C cirrhosis.

Im GY, Dieterich DT.

Gastroenterol Hepatol (N Y). 2012 Nov;8(11):727-65.

3.

Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, Rufian S, de la Mata M, Briceño J, Cillero PL, Heaton N.

World J Hepatol. 2013 May 27;5(5):237-50. doi: 10.4254/wjh.v5.i5.237.

4.

Efficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis C.

Yan Z, Fan K, Wang X, Mao Q, Deng G, Wang Y.

Gastroenterol Res Pract. 2012;2012:302093. doi: 10.1155/2012/302093. Epub 2012 Dec 3.

5.

Treatment of patients with HCV related cirrhosis: many rewards with very few risks.

D'Ambrosio R, Aghemo A.

Hepat Mon. 2012 Jun;12(6):361-8. doi: 10.5812/hepatmon.6095. Epub 2012 Jun 30.

6.

Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.

López-Cortés LF, Ruiz-Valderas R, Jimenez-Jimenez L, González-Escribano MF, Torres-Cornejo A, Mata R, Rivero A, Pineda JA, Marquez-Solero M, Viciana P; Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas.

PLoS One. 2012;7(1):e28115. doi: 10.1371/journal.pone.0028115. Epub 2012 Jan 3.

7.

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.

Yang JF, Kao YH, Dai CY, Huang JF, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML.

Hepatol Int. 2010 Aug 9;4(4):732-40. doi: 10.1007/s12072-010-9208-0.

8.

Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.

Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, Hoofnagle JH.

Aliment Pharmacol Ther. 2010 May;31(9):1018-27. doi: 10.1111/j.1365-2036.2010.04263.x. Epub 2010 Jan 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk